EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Receptor-binding autoantibodies are not associated with post-COVID fatigue

Martin Achleitner, Juliane Dänhardt, Romina Kardashi, Nicole Toepfner, Katja de With, Zhenfei Li, Natalia Jarzebska, Roman N Rodionov, Stefan R Bornstein, Charlotte Steenblock

Brain, Behavior, & Immunity - Health · 2026-12 · 58 · 101393

DOI: 10.1016/j.bbih.2026.101393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, & Immunity - Health, 2026-12. Verfasst von Martin Achleitner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Persistent fatigue is a common symptom following SARS-CoV-2 infection, but its underlying mechanisms remain incompletely understood. Autoantibodies targeting G-protein coupled receptors and other neurotransmitter-related receptors have been proposed as potential biomarkers or mediators of post-COVID symptoms. However, their association with post-COVID fatigue remains unclear. Therefore, in the current study, we investigated receptor-binding autoantibodies against 13 neurotransmitter-related receptors in 206 participants with prior infection with SARS-CoV-2. Three groups of patients were enrolled: controls with no persistent fatigue, patients experiencing new-onset post-infection fatigue, and a group of patients who already suffered from fatigue before their infection with SARS-CoV-2. Fatigue was assessed using a standardized self-reported fatigue questionnaire. We found no significant differences in the concentrations of the measured receptor-binding autoantibodies between participants with new-onset fatigue, pre-existing fatigue, and controls without persistent fatigue. In multivariable analyses, none of the individual antibody concentrations was significantly associated with new-onset fatigue after adjustment for age, sex, and time since infection and correction for multiple testing. Individual antibody concentrations were also not associated with fatigue severity. The proportion of participants exceeding manufacturer-defined reference values did not differ significantly between the study groups. Similarly, cumulative antibody positivity was not associated with fatigue severity. In conclusion, in this cohort of SARS-CoV-2-infected participants, we found no evidence that concentrations of the measured receptor-binding autoantibodies are associated with post-COVID fatigue or fatigue severity. These findings do not support the use of these antibodies as stand-alone biomarkers of post-COVID fatigue. Because all participants had previously experienced SARS-CoV-2 infection, the study cannot determine whether infection itself alters antibody concentrations. Furthermore, the binding assays do not establish whether the detected antibodies have functional receptor activity. These findings underscore the urgent need for longitudinal studies with comprehensive clinical phenotyping and functional antibody assays are needed to further investigate the potential role of receptor-binding autoantibodies in post-COVID symptoms.

Schlagwörter

Stichwörter der Autor:innen

AutoantibodiesCOVID-19FatigueLong COVIDNeurotransmittersPost-COVID-19 condition

Autor:innen und Institutionen

  • Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Division of Infectious Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland.

Förderung

  • German Research Foundation

Zitieren

APA

Achleitner, M., Dänhardt, J., Kardashi, R., Toepfner, N., de With, K., Li, Z., Jarzebska, N., Rodionov, R. N., Bornstein, S. R., & Steenblock, C. (2026). Receptor-binding autoantibodies are not associated with post-COVID fatigue. Brain, Behavior, & Immunity - Health, 58, 101393. https://doi.org/10.1016/j.bbih.2026.101393

Vancouver

Achleitner M, Dänhardt J, Kardashi R, Toepfner N, de With K, Li Z, et al. Receptor-binding autoantibodies are not associated with post-COVID fatigue. Brain, Behavior, & Immunity - Health. 2026;58:101393. doi:10.1016/j.bbih.2026.101393

BibTeX
@article{Achleitner2026,
  author = {Achleitner, Martin and Dänhardt, Juliane and Kardashi, Romina and Toepfner, Nicole and de With, Katja and Li, Zhenfei and Jarzebska, Natalia and Rodionov, Roman N and Bornstein, Stefan R and Steenblock, Charlotte},
  title = {Receptor-binding autoantibodies are not associated with post-COVID fatigue},
  journal = {Brain, Behavior, & Immunity - Health},
  year = {2026},
  volume = {58},
  pages = {101393},
  doi = {10.1016/j.bbih.2026.101393}
}
Kostenlos starten →